Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD (2019) Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, et al. Journal article G-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma (2019) Pont MJ, Hill T, Cole GO, Abbott JJ, Kelliher J, Salter AI, Hudecek M, et al. Journal article Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia (2018) Middeke JM, Rollig C, Kramer M, Kramer A, Bochtler T, Scholl S, Hochhaus A, et al. Conference contribution Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease (2018) Aziz MD, Shah J, Kapoor U, Dimopoulos CN, Ayuk FA, Hogan WJ, Schreiner E, et al. Conference contribution EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia (2018) Stasik S, Middeke JM, Kraemer M, Rollig C, Kramer A, Scholl S, Hochhaus A, et al. Conference contribution Comorbidities Are Frequent in Older Patients with De Novo Acute Lymphoblastic Leukemia (ALL) and Correlate with Induction Mortality: Analysis of More Than 1200 Patients from GMALL Data Bases (2018) Wermann WK, Viardot A, Kayser S, Alakel N, Elmaagacli A, Faul C, Fiedler W, et al. Conference contribution Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study (2018) Hochhaus A, Saussele S, Baerlocher GM, Bruemmendorf TH, Burchert A, La Rosee P, Hasford J, et al. Conference contribution MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study (2018) Raab MS, Chatterjee M, Goldschmidt H, Agis H, Blau I, Einsele H, Engelhardt M, et al. Conference contribution Prolyl Hydroxylase 3 (Phd3) Is a Therapeutic Target in Isocitrate Dehydrogenase 1 (IDH1) Mutated Acute Myeloid Leukemia (2018) Chaturvedi A, Cruz MMA, Goparaju R, Gabdoulline R, Schottmann R, Goerlich K, Kloos A, et al. Conference contribution DNA Damage-Response Pathway in Lymphoma Determines Interactions with Macrophages By Altered PD-Li Expression and Fxosome Formation (2018) Vorholt D, Izquierdo-Alvarez E, Sackey B, Schmitz J, Nickel N, Blakemore S, Knittel G, et al. Conference contribution